Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Enrolling By Invitation
18 years - 99 years
All
Phase
2
40 participants needed
1 Location
Brief description of study
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Acute Myeloid Leukemia - Adult,Myelodysplastic Syndromes,Refractory Acute Myeloid Leukemia
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or older, Documented diagnosis of MDS or Diagnosed AML
Updated on
04 Aug 2024.
Study ID: 850116
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
